Medicus Pharma (MDCX) awards CMO 250,000 options at $0.36 strike

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options covering 250,000 Common Shares. The options carry an exercise price of $0.36 per share and expire on June 3, 2031. According to the disclosure, the options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year. Following this award, Faisal holds 250,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mehmud Faisal

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	250,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 250,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 250,000 options Exercise price: $0.36 per share Underlying shares: 250,000 Common Shares +2 more

5 metrics

Options granted 250,000 options Grant to Chief Medical Officer on June 3, 2026

Exercise price $0.36 per share Stock option exercise price for Common Shares

Underlying shares 250,000 Common Shares Shares underlying granted stock options

Expiration date June 3, 2031 Stock option expiration

Post-grant option holdings 250,000 options Total options held following transaction

Key Terms

Stock Option (right to buy), Common Shares, Grant, award, or other acquisition, vest quarterly in four equal installments

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest quarterly in four equal installments financial

"The option is scheduled to vest quarterly in four equal installments over one year."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehmud Faisal

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		250,000		(1)	06/03/2031	Common Shares	250,000	$0	250,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Faisal Mehmud	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medicus Pharma (MDCX) report for Mehmud Faisal?

Medicus Pharma reported that Chief Medical Officer Mehmud Faisal received a grant of 250,000 stock options. These options relate to Common Shares and represent compensation rather than an open-market purchase or sale of shares.

What is the exercise price of the new stock options granted by Medicus Pharma (MDCX)?

The granted stock options have an exercise price of $0.36 per share. This means Faisal can buy Medicus Pharma Common Shares at $0.36 once the options vest and are exercised, subject to the award’s terms.

When do Mehmud Faisal’s Medicus Pharma (MDCX) stock options vest and expire?

The options were granted on June 3, 2026 and will vest quarterly in four equal installments over one year. They have an expiration date of June 3, 2031, providing a multi-year window to exercise after vesting.

How many Medicus Pharma (MDCX) stock options does Mehmud Faisal hold after this grant?

Following this award, Mehmud Faisal is reported to hold 250,000 stock options directly. Each option is linked to one Common Share of Medicus Pharma, according to the filing’s underlying security description.

Is the Medicus Pharma (MDCX) Form 4 transaction a market buy or sell of shares?

No, the Form 4 reports a grant of derivative securities, specifically stock options. The transaction is classified as a grant, award, or other acquisition, not an open-market purchase or sale of existing Common Shares.